Marshall Wace LLP Invests $1.10 Million in Harrow Health (NASDAQ:HROW)

Marshall Wace LLP purchased a new stake in Harrow Health (NASDAQ:HROW) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 221,693 shares of the company’s stock, valued at approximately $1,104,000. Marshall Wace LLP owned about 0.90% of Harrow Health as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of HROW. FineMark National Bank & Trust acquired a new stake in Harrow Health during the first quarter worth about $113,000. EAM Global Investors LLC acquired a new stake in Harrow Health during the first quarter worth about $171,000. Institutional & Family Asset Management LLC acquired a new stake in Harrow Health during the first quarter worth about $195,000. Alambic Investment Management L.P. acquired a new stake in Harrow Health during the first quarter worth about $252,000. Finally, Birchview Capital LP acquired a new stake in Harrow Health during the first quarter worth about $896,000. 32.08% of the stock is currently owned by institutional investors.

In other Harrow Health news, Director Robert J. Kammer sold 10,000 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $5.78, for a total transaction of $57,800.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Robert J. Kammer sold 6,500 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $7.91, for a total transaction of $51,415.00. The disclosure for this sale can be found here. Insiders have sold a total of 26,500 shares of company stock worth $154,915 over the last three months. Insiders own 12.43% of the company’s stock.

HROW traded down $0.05 during midday trading on Friday, reaching $7.82. 160,529 shares of the company’s stock were exchanged, compared to its average volume of 277,005. The company has a quick ratio of 3.22, a current ratio of 3.43 and a debt-to-equity ratio of 0.47. The company has a market cap of $193.19 million, a price-to-earnings ratio of 12.82 and a beta of 0.05. The company’s 50-day moving average is $6.99. Harrow Health has a one year low of $2.22 and a one year high of $8.99.

Harrow Health (NASDAQ:HROW) last released its earnings results on Thursday, May 9th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.14). The business had revenue of $12.29 million for the quarter, compared to analyst estimates of $12.10 million. Harrow Health had a return on equity of 100.84% and a net margin of 65.84%. Analysts predict that Harrow Health will post -0.1 EPS for the current fiscal year.

A number of brokerages have commented on HROW. Zacks Investment Research cut shares of HEXO from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. ValuEngine upgraded shares of YPF from a “sell” rating to a “hold” rating in a research note on Monday, June 24th. Finally, TheStreet cut shares of ZTO Express (Cayman) from a “b+” rating to a “c” rating in a research note on Wednesday, May 1st.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Featured Story: The basics of gap trading strategies

Institutional Ownership by Quarter for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.